{
 "PrintNo":"S5439","Version":"A","Session":2023,"Chamber":"SENATE","BillType":"Senate",
 "Published":"2023-03-06T09:35:22.010269Z","Status":"IN_SENATE_COMM","Committee":"Health",
 "Milestones":[{"Type":"IN_SENATE_COMM","Date":"2024-01-03","Committee":"Health"}],
 "Actions":[
  {"Text":"REFERRED TO HEALTH","Date":"2023-03-06","Chamber":"SENATE"},
  {"Text":"AMEND AND RECOMMIT TO HEALTH","Date":"2023-11-01","Chamber":"SENATE"},
  {"Text":"PRINT NUMBER 5439A","Date":"2023-11-01","Chamber":"SENATE","Version":"A"},
  {"Text":"REFERRED TO HEALTH","Date":"2024-01-03","Chamber":"SENATE","Version":"A"}
 ],
 "Sponsors":[{"ID":1232,"Name":"James Skoufis","Short":"SKOUFIS"}],
 "Title":"Designates Xylazine as a schedule III depressant",
 "Summary":"Designates Xylazine as a schedule III depressant.","LawSection":"Public Health Law",
 "LawCode":"Amd ยง3306, Pub Health L",
 "ActClause":"AN ACT to amend the public health law, in relation to designating Xylazine as a schedule III depressant",
 "SameAsPrintNo":"A5914-2023"
}